- MDVN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $108.2 million.
- MDVN is up 2.1% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in MDVN with the Ticky from Trade-Ideas. See the FREE profile for MDVN NOW at Trade-Ideas More details on MDVN: Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. MDVN has a PE ratio of 318.9. Currently there are 10 analysts that rate Medivation a buy, 1 analyst rates it a sell, and 4 rate it a hold. The average volume for Medivation has been 915,200 shares per day over the past 30 days. Medivation has a market cap of $7.1 billion and is part of the health care sector and drugs industry. The stock has a beta of -0.45 and a short float of 6.7% with 3.53 days to cover. Shares are up 47.8% year-to-date as of the close of trading on Tuesday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.